RCM
HALO icon

Raleigh Capital Management’s Halozyme HALO Stock Holding History

Raleigh Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$312 – 605
2025
Q2 		$312 Buy
+6
New +$341 ﹤0.01% 537
2023
Q2 		– Sell
-61
Closed -$2.33K – 877
2023
Q1 		$2.33K Buy
+61
New +$2.86K ﹤0.01% 757

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raleigh Capital Management's HALO Position: Q3 2025 in Review

Raleigh Capital Management sold out of Halozyme (HALO) in Q3 2025, closing a stake of 6 shares — an estimated $312 sold.

Raleigh Capital Management first reported a position in HALO in Q1 2023 and held it in 2 quarters. The position peaked at $2.33K in Q1 2023. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • Raleigh Capital Management reported no remaining Halozyme position as of Q3 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 6 Halozyme shares in Q3 2025, an estimated $312.
  • Raleigh Capital Management first reported a position in Halozyme in Q1 2023 and held it in 2 quarters.
  • Raleigh Capital Management's Halozyme position peaked at $2.33K in Q1 2023.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Raleigh Capital Management's 13F filing for Q3 2025, filed 4 Nov 2025.